Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its products include INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 2 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; that has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that is in Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension, pulmonary hypertension associated with pulmonary edema from high altitude sickness, and COVID-19 patients. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.
IPO Year: 2015
Exchange: NASDAQ
Website: bellerophon.com
| Date | Price Target | Rating | Analyst |
|---|
4 - Bellerophon Therapeutics, Inc. (0001600132) (Issuer)
4 - Bellerophon Therapeutics, Inc. (0001600132) (Issuer)
4 - Bellerophon Therapeutics, Inc. (0001600132) (Issuer)
4 - Bellerophon Therapeutics, Inc. (0001600132) (Issuer)
4 - Bellerophon Therapeutics, Inc. (0001600132) (Issuer)
4 - Bellerophon Therapeutics, Inc. (0001600132) (Issuer)
4 - Bellerophon Therapeutics, Inc. (0001600132) (Issuer)
4 - Bellerophon Therapeutics, Inc. (0001600132) (Issuer)
4 - Bellerophon Therapeutics, Inc. (0001600132) (Issuer)
4 - Bellerophon Therapeutics, Inc. (0001600132) (Issuer)
SC 13G/A - Bellerophon Therapeutics, Inc. (0001600132) (Subject)
SC 13G/A - Bellerophon Therapeutics, Inc. (0001600132) (Subject)
SC 13G - Bellerophon Therapeutics, Inc. (0001600132) (Subject)
SC 13D/A - Bellerophon Therapeutics, Inc. (0001600132) (Subject)
SC 13D/A - Bellerophon Therapeutics, Inc. (0001600132) (Subject)
SC 13G/A - Bellerophon Therapeutics, Inc. (0001600132) (Subject)
SC 13D/A - Bellerophon Therapeutics, Inc. (0001600132) (Subject)
SC 13G/A - Bellerophon Therapeutics, Inc. (0001600132) (Subject)
SC 13G - Bellerophon Therapeutics, Inc. (0001600132) (Subject)
SC 13D/A - Bellerophon Therapeutics, Inc. (0001600132) (Subject)
8-K - Bellerophon Therapeutics, Inc. (0001600132) (Filer)
DEFA14A - Bellerophon Therapeutics, Inc. (0001600132) (Filer)
DEFA14A - Bellerophon Therapeutics, Inc. (0001600132) (Filer)
8-K - Bellerophon Therapeutics, Inc. (0001600132) (Filer)
8-K - Bellerophon Therapeutics, Inc. (0001600132) (Filer)
8-K - Bellerophon Therapeutics, Inc. (0001600132) (Filer)
DEFA14A - Bellerophon Therapeutics, Inc. (0001600132) (Filer)
25-NSE - Bellerophon Therapeutics, Inc. (0001600132) (Subject)
8-K - Bellerophon Therapeutics, Inc. (0001600132) (Filer)
8-K - Bellerophon Therapeutics, Inc. (0001600132) (Filer)
Trial did not meet its primary endpoint related to the change in moderate to vigorous physical activity INOpulse® was safe and well-tolerated, consistent with the overall safety profile demonstrated in Phase 2 and other INOpulse® programs in PH-COPD and PH-SarcoidosisCompany to host conference call and webcast with slides today at 8:30 AM ET WARREN, N.J., June 05, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced top-line results from its pivotal Phase 3 REBUILD clinical trial evaluating the safety and efficacy of INO
WARREN, N.J., May 11, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that the last patient has completed blinded treatment in the ongoing Phase 3 REBUILD study of INOpulse®, a proprietary pulsatile nitric oxide delivery system, for the treatment of fibrotic interstitial lung disease (fILD). The Company expects to report top-line results from this study in mid-2023. "The successful and timely completion of the blinded treatment phase of our pivotal Phase 3 REBUILD trial represents a key milestone in our INOpulse® de
Completed Enrollment in INOpulse® REBUILD Phase 3 trial; Pivotal Top-line Data Expected in Mid-2023Signed License Agreement with Baylor BioSciences to Commercialize INOpulse® in Greater ChinaStrengthened Balance Sheet Through $5 Million Registered Direct Offering with Life Sciences-focused Institutional Investor WARREN, N.J., March 31, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the year ended December 31, 2022. "We have achieved significant recent pro
WARREN, N.J., March 06, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that it has entered into a subscription agreement with a life sciences-focused institutional investor to sell, in a registered direct offering, 718,474 shares of common stock at a price of $2.00 per share and 1,781,526 prefunded warrants at a price of $1.99 per pre-funded warrant for total gross proceeds of approximately $5 million, before deducting estimated offering expenses. The offering is expected to close on March 7, 2023, subject to the sa
WARREN, N.J., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced clearance of its Investigational New Drug (IND) application from the Center for Drug Evaluation of China's National Medical Products Administration (NMPA) to conduct a Phase 3 clinical trial to support the registration of INOpulse® for the treatment of fibrotic interstitial lung disease (fILD) in China. The study will utilize Moderate to Vigorous Physical Activity (MVPA) as the primary endpoint and be conducted in collaboration with Bellerophon's
WARREN, N.J., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that the last patient has been enrolled in the ongoing Phase 3 REBUILD study of INOpulse®, a proprietary pulsatile nitric oxide delivery system, for the treatment of fibrotic interstitial lung disease (fILD). The Company now expects to report pivotal top-line results in mid- 2023. "We are pleased to have completed enrollment in this important study sooner than previously anticipated, which represents a significant milestone for Bellerophon, our
WARREN, N.J., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that it has entered into a license agreement for the development and commercialization of INOpulse® with Baylor BioSciences, a life sciences company dedicated to the development and commercialization of innovative medical products for Greater China. Under the terms of the license agreement, Bellerophon will receive a license payment of $6 million, payable within 90 days subject to certain closing conditions set forth in the agreement. Additionall
WARREN, N.J., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the third quarter ended September 30, 2022. "We continue to achieve important progress in advancing the ongoing REBUILD Phase 3 trial of INOpulse® for the treatment of fibrotic Interstitial Lung Disease (fILD)," said Naseem Amin, M.D., Chairman of Bellerophon's Board of Directors. "With the recent U.S. Food and Drug Administration (FDA) acceptance of the reduction in the study sample si
New study size of 140 patients for the REBUILD Study, without modifying trial objective or endpoints and maintaining power of >90% for the primary endpointIndependent Data Monitoring Committee agreed that the new targeted study size is appropriateEnrollment now expected to conclude in Q1 2023, with pivotal top-line data readout anticipated in Q3 2023 WARREN, N.J., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, announced today that the U.S. Food and Drug Administration (FDA) has accepted the Company's proposal to reduce t
WARREN, N.J., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the second quarter ended June 30, 2022. "The Bellerophon team continues to advance our late-stage INOpulse® inhaled nitric oxide therapy platform for the treatment of fibrotic interstitial lung disease, or fILD, and pulmonary hypertension associated with sarcoidosis, or PH-Sarc," said Naseem Amin, M.D., Chairman of Bellerophon's Board of Directors. "Enrollment is steadily proceeding in o
WARREN, N.J., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the second quarter ended June 30, 2021. "We continue to progress our INOpulse® inhaled nitric oxide therapy in multiple areas of significant unmet need," said Fabian Tenenbaum, Chief Executive Officer of Bellerophon. "Our ongoing pivotal Phase 3 REBUILD study for fibrotic interstitial lung disease, or fILD, patients at risk of associated pulmonary hypertension is progressing well and con
WARREN, N.J., May 26, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced the appointment of Naseem Amin, M.D., as Chairman of its Board of Directors, effective immediately. Dr. Amin, who has served as an Independent Director since 2015, will succeed Jonathan Peacock, who is retiring from the Company's Board. "It has been a privilege to work alongside the talented Bellerophon team over the past several years and to guide the Company's evolution into a late-stage development company," said Mr. Peacock. "With a number of
Trial did not meet its primary endpoint related to the change in moderate to vigorous physical activity INOpulse® was safe and well-tolerated, consistent with the overall safety profile demonstrated in Phase 2 and other INOpulse® programs in PH-COPD and PH-SarcoidosisCompany to host conference call and webcast with slides today at 8:30 AM ET WARREN, N.J., June 05, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced top-line results from its pivotal Phase 3 REBUILD clinical trial evaluating the safety and efficacy of INO
Gainers Bellerophon Therapeutics (NASDAQ:BLPH) stock moved upwards by 17.1% to $0.12 during Friday's after-market session. Trading volume for this security closed at 2.1 million, accounting for 1394.7% of its average full-day volume over the last 100 days. The company's market cap stands at $1.4 million. Cingulate (NASDAQ:CING) stock increased by 12.59% to $0.58. The company's market cap stands at $10.0 million. Rain Oncology (NASDAQ:RAIN) stock rose 11.11% to $1.1. Rain Oncology's trading volume hit 98.3K shares by close, accounting for 45.0% of its average volume over the last 100 days. The company's market cap stands at $40.0 million. Artelo Biosciences (NASDAQ:ARTL) shares rose 9.72%
Gainers Bio-Path Hldgs (NASDAQ:BPTH) shares rose 60.6% to $0.63 during Friday's regular session. Bio-Path Hldgs's stock is trading at a volume of 111.1 million shares as of 13:30 EST. This is 15820.7% of its average full-day volume over the last 100 days. The company's market cap stands at $7.2 million. Processa Pharma (NASDAQ:PCSA) stock moved upwards by 22.69% to $0.41. The current volume of 5.1 million shares is 2367.4% of Processa Pharma's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $9.9 million. Harpoon Therapeutics (NASDAQ:HARP) stock increased by 20.66% to $3.97. As of 13:30 EST, Harpoon Therapeutics's stock is trad
Gainers Sigma Additive Solutions, Inc. (NASDAQ:SASI) shares jumped 196% to $7.34 after the company announced the signing of a definitive agreement for the acquisition of NextTrip Holdings, Inc. Bio-Path Holdings, Inc. (NASDAQ:BPTH) shares climbed 102% to $0.7961 after gaining more than 6% on Thursday. Shift Technologies, Inc. (NASDAQ:SFT) gained 60% to $0.2145, after falling around 21% on Thursday. C3is Inc. (NASDAQ:CISS) gained 32% to $0.5625. Comtech Telecommunications Corp. (NASDAQ:CMTL) shares climbed 30.6% to $10.63 after posting better-than-expected fourth-quarter results. Versus Systems Inc. (NASDAQ:VS) shares climbed 29.1% to $0.4246 after jumping more than 52% on Thursday.
U.S. stocks traded mostly higher this morning, with the Dow Jones gaining more than 200 points on Friday. Following the market opening Friday, the Dow traded up 0.74% to 33,880.85 while the NASDAQ rose 0.04% to 13,579.61. The S&P 500 also rose, gaining, 0.41% to 4,367.33. Check This Out: Top 5 Tech And Telecom Stocks That May Explode This Month Leading and Lagging Sectors Energy shares climbed by 1.7% on Friday. In trading on Friday, information technology shares rose by just 0.1%. Top Headline JPMorgan Chase & Co (NYSE:JPM) reported better-than-expected earnings for its third quarter on Friday. JPMorgan reported quarterly net revenue (managed) of $40.7 billion, up 21% Y
Gainers Bio-Path Hldgs (NASDAQ:BPTH) stock rose 132.2% to $0.92 during Friday's pre-market session. The company's market cap stands at $10.4 million. Redhill Biopharma (NASDAQ:RDHL) stock moved upwards by 34.4% to $0.5. The company's market cap stands at $2.9 million. Akari Therapeutics (NASDAQ:AKTX) shares rose 14.52% to $4.02. The market value of their outstanding shares is at $20.3 million. TRACON Pharma (NASDAQ:TCON) stock moved upwards by 14.42% to $0.22. The market value of their outstanding shares is at $6.7 million. Petros Pharma (NASDAQ:PTPI) shares increased by 13.94% to $1.74. The company's market cap stands at $3.6 million. Sera Prognostics (NASDAQ:SERA) shares increased by
Gainers Bio-Path Hldgs (NASDAQ:BPTH) stock increased by 158.8% to $1.02 during Thursday's after-market session. Today's trading volume for this security ended up closing at 18.9 million shares, which is 5623.9 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $11.6 million. Comera Life Sciences (NASDAQ:CMRA) shares increased by 63.0% to $0.52. At the close, Comera Life Sciences's trading volume reached 572.6K shares. This is 1127.9% of its average volume over the last 100 days. The market value of their outstanding shares is at $15.9 million. Scinai Immunotherapeutics (NASDAQ:SCNI) stock rose 17.02% to $0.77. The company's market cap
Tuesday saw 132 companies set new 52-week lows. Facts of Interest About Today's 52-Week Lows: Corning (NYSE:GLW) was the largest, in terms of market cap, to set a new 52-week low. Wheeler Real Estate IT (NASDAQ:WHLR) was the smallest company when considering market cap to set a new 52-week low. Fortress Biotech (NASDAQ:FBIO) saw the largest move of the companies, as shares plummetted 1350.03% to hit a new 52-week low. Insulet (NASDAQ:PODD)'s stock made the biggest bounce back, actually moving up 0.0% shortly after hitting a new 52-week low. Here are all the stocks that set new 52-week lows on Tuesday: Corning (NYSE:GLW) shares were up 0.2% for the day, having made a 52-week lo
Friday's session saw 59 companies set new 52-week lows. Interesting Facts About Today's 52-Week Lows: Bristol-Myers Squibb (NYSE:BMY) was the largest firm by market cap to set a new 52-week low. BitNile Metaverse (NASDAQ:BNMV) was the smallest company in terms of market cap to set a new 52-week low. Tonix Pharmaceuticals (NASDAQ:TNXP) saw the largest move of the companies, as shares plummetted 38.2% to hit a new 52-week low. ClearPoint Neuro (NASDAQ:CLPT)'s stock bounced back the most, actually rising 0.0% after reaching its new 52-week low. The following stocks created new 52-week lows on Friday: Bristol-Myers Squibb (NYSE:BMY) shares were up 0.07% for the day, having made a
Gainers Reata Pharmaceuticals (NASDAQ:RETA) shares rose 52.2% to $165.24 during Friday's pre-market session. The market value of their outstanding shares is at $6.2 billion. Bluejay Diagnostics (NASDAQ:BJDX) shares rose 35.7% to $7.26. The company's market cap stands at $7.4 million. SIGA Technologies (NASDAQ:SIGA) stock increased by 26.74% to $6.45. The company's market cap stands at $459.7 million. Homology Medicines (NASDAQ:FIXX) shares moved upwards by 22.34% to $1.15. The market value of their outstanding shares is at $66.4 million. Creative Medical Tech (NASDAQ:CELZ) shares rose 17.43% to $6.6. The market value of their outstanding shares is at $9.2 million. Asensus Surgical (AME
Gainers Unique Fabricating, Inc. (NASDAQ:UFAB) shares surged 62.6% to $0.3512 in pre-market trading after gaining 12% on Thursday. Greenbrook TMS Inc. (NASDAQ:GBNH) rose 34.3% to $0.6647 in pre-market trading after jumping 90% on Thursday. SIGA Technologies, Inc. (NASDAQ:SIGA) gained 29.3% to $6.58 in pre-market trading after the company announced a $138 million US government contract for oral and IV TPOXX treatment. Homology Medicines, Inc. (NASDAQ:FIXX) shares gained 24.5% to $1.17 in pre-market trading after the company announced plans to evaluate strategic options. The company is also reducing its workforce by 87%. Inpixon (NASDAQ:INPX) shares rose 20% to $0.2424 in pre-market tr